A ground-breaking initiative between pharmaceutical companies, the UK’s GSK and US-based Regeneron, could usher in a new era of drug development for a wide range of diseases.
Apotex, the Canadian owned pharmaceutical company, is investing $184 million as part of expansion plans in the US.
Outsourcing services provider PCI Pharma Services (PCI) has significantly expanded its serialisation capability.
Emergent BioSolutions has signed a $100 million two-year contract with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery of BioThrax to the US Strategic National Stockpile (SNS).
UK patients will benefit from access to the most cost-effective treatments nearly 5 months faster after changes to the NICE drug evaluation process were approved.
The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), has welcomed the Prime Minister’s speech on the Government’s negotiating objectives for exiting the EU.
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul injection in Europe, the Middle East and North Africa.
The first consignment of British manufactured medicines has been exported to Iraq by a new Yorkshire pharmaceuticals wholesaler and distributor set up to give Iraqi people access to high-quality treatments.
The US Food & Drug administration has approved its first treatment for mestastic Merkel cell carcinoma, a rare and aggressive type of skin cancer.
Newron Pharmaceuticals has gained approval from the US Food and Drug Administration for Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes.